嗜黏蛋白阿克曼菌在疾病中的保护性作用及机制研究进展

嗜黏蛋白阿克曼菌(Akkermansia muciniphila,Akk)是人类肠道正常存在的常见共生菌,丰度约占肠菌的1%-3%。Akk是极少数已知在肠道平衡态下仍能引发T细胞依赖性免疫作用的肠菌,提示该菌可能参与正常肠道免疫耐受过程。疾病和模型动物研究表明,Akk在改善宿主代谢功能和免疫应答方面具有重要作用,近期引起广泛关注。目前相关研究大多集中在Akk与疾病的相关性上,尚无系统阐述其作用机制的研究。本文对Akk与人体几大重要系统疾病和免疫之间的关联及其作用机制进行论述,以期为Akk的有效利用提供证据和思路。     

乳杆菌对致病假单胞菌的抑制作用研究进展*

假单胞菌污染事件在临床就医和日常饮食中频发,屡次产生致病、致死等恶劣后果,有效抑制致病假单胞菌并降低其耐药性作为解决该问题的关键手段,是目前的研究重点。相关研究表明益生菌等天然活性成分对假单胞菌产生多方面影响,以应用范围最广的益生菌——乳杆菌为例,综合国内外最新研究进展,论述了乳杆菌对假单胞菌的生物膜结构、生长活性、生物毒性、黏附细胞表面能力及被假单胞菌感染后的小鼠等产生的影响。深入挖掘乳杆菌等益生菌及其代谢产物成分的作用机制,是防治假单胞菌等微生物污染和感染的关键。     

不同类型益生菌制剂在胃肠道中耐受程度的对比

目的对市场销售的几种不同类型益生菌制剂进行胃、肠液耐受程度比较,评价各益生菌制剂活菌数量,为临床选择益生菌制剂提供参考。方法选择7种菌粉及某颗粒益生菌、国产某晶球、日本产某晶球、某胶囊益生菌、圣邦步步佳肠释益生菌共12种口服益生菌产品,在崩解时限仪中加入人工胃液进行崩解试验,在0.0 h、0.5 h、1.0 h、1.5 h和2.0 h时吸取上述样品并进行浓度梯度稀释,并在MRS固体培养基上培养后进行活菌计数。在上述5个时间点吸取部分益生菌-胃液混合物(针对益生菌粉末)或取出益生菌产品(针对晶球、肠溶胶囊、肠释益生菌)换人工肠液再进行40 min崩解,在MRS固体培养基上培养后进行活菌计数。结果粉末状益生菌制剂对人工胃液的耐受能力普遍较差。某颗粒益生菌、国产某晶球、日本产某晶球、某胶囊益生菌、圣邦步步佳肠释益生菌在人工胃液中不崩解。圣邦步步佳肠释益生菌在人工肠液中40 min完全崩解且活菌数峰值较高。结论圣邦步步佳肠释益生菌对人工胃、肠液耐受能力较强,且活菌数较高。     

动物微生态制剂在宠物领域的应用现状及研究进展

动物微生态制剂是在动物微生态理论指导下,采用益生菌制成的活菌制剂。本文主要结合国内外的研究资料,对动物微生态制剂在宠物领域的应用现状、研究进展及存在的问题进行综述。     

肠道益生菌预防和治疗食物过敏的研究进展

目前 ,食物过敏的发生率在人群 ,尤其是婴幼儿中逐年增高。其治疗策略仍是以排除致敏食物为主 ,但效果欠佳。由于益生菌所独有的生物学特点和肠道粘膜免疫反应的特异性 ,使肠道益生菌疗法作为治疗食物过敏的一种新兴疗法 ,日益受到人体的重视。本文就其临床疗效、作用机制、选菌原则、使用安全性等问题作一综述 ,以期加强对益生菌的研究和应用。1　益生菌治疗食物过敏的疗效研究进展益生菌在人体中主要以双歧杆菌和乳酸杆菌为主 ,具有粘附肠粘膜、稳定胆汁酸、使用安全 ,是人类肠道共生细菌等共同特点。作为肠道微生态的平衡者和肠道粘膜免…     

两种生物状态肠道益生菌的粘附和粘附拮抗效应的对比研究

目的:研究活菌和灭活菌两种生物状态的肠道主要益生菌--德氏乳杆菌、双歧杆菌和肠球菌对肠黏膜上皮细胞粘附性及其对肠道几种常见病原菌的粘附拮抗效应.方法:用光镜和电镜技术分析了两种生物状态的三种益生菌对肠黏膜上皮细胞的粘附指数,通过排除实验、竞争实验和替代实验研究了两种生物状态益生菌对侵袭性大肠埃希菌、产毒性大肠埃希菌和痢疾志贺菌的粘附拮抗效应,应用平板扩散法观察了三种益生菌的代谢乏液对上述肠道病原菌的抑制能力.结果:德氏乳杆菌和肠球菌的灭活状态较活菌状态对肠黏膜上皮细胞的粘附性显著增高,双歧杆菌经灭活后对细胞的粘附性与活菌相比差异无显著性,两种生物状态的三种益生菌对肠道致病菌均具有粘附拮抗作用.滤过后的德氏乳杆菌、双歧杆菌和肠球菌的代谢乏液对侵袭性大肠埃希菌、产毒性大肠埃希菌和痢疾志贺菌均具有较明显的抑制作用,经42℃、65℃和100℃加热不影响德氏乳杆菌和双歧杆菌代谢乏液的抑菌作用.结论:灭活状态的德氏乳杆菌、双歧杆菌和肠球菌是具有潜在开发价值的微生态制剂.     

益生菌在炎症性肠病治疗中的研究进展

益生菌（Probiotics）是一类能够促进肠道微生物菌群平衡,对宿主健康或生理功能产生有益作用的活性微生物。目前广泛应用于生命健康领域、科学研究、生物工程、工农业以及食品安全。大量国内外研究表明益生菌在降血压、降血糖、降血脂、抗过敏、抗炎、调节免疫、维持肠道菌群平衡等方面具有积极作用。炎症性肠病的病因和发病机制尚未完全明确,现多认为与遗传、环境、感染、免疫以及肠道微生物多因素相互作用有关。益生菌通过多种机制介导,在临床治疗炎症性肠病中扮演着重要角色。     

益生菌的免疫调节作用及其相关应用研究进展

益生菌的定义来自希腊语,益生菌是指:当摄入足够的剂量时可以对宿主产生有益影响的活的微生物。目前,全球对益生菌及其相关制剂的研究日益受到重视,益生菌在食品、营养品及医药领域的研究也不断深入,益生菌的免疫调节机制主要包括黏膜屏障作用、增强单核—巨噬细胞的吞噬作用、促进sIgA生成等。此外,益生菌还应用于临床相关疾病的治疗,改善受损肝脏的功能,缓解肠易激综合征的临床症状,通过调节脂肪代谢及胰岛素敏感性预防2型糖尿病的发生,预防结直肠肿瘤细胞生长及减轻肠道炎症等。本文主要就益生菌的上述相关研究进展进行综述,为益生菌的研究及相关应用提供参考。     

粪菌移植和益生菌在复发性艰难梭菌感染和炎症性肠病中的应用进展

聚集在人体肠道的菌群对维持机体正常的生理功能具有重要作用,肠道菌群的失调会导致复发性艰难梭菌感染及炎症性肠病等疾病。粪菌移植是将健康供者肠道内的功能菌群转移到患病个体的肠道内,重建患者的肠道微生态环境,从而达到治疗的目的。研究发现,粪菌移植在治疗复发性艰难梭菌感染方面表现出较高的治愈率,同时对炎症性肠病有积极的疗效。益生菌是一类能发挥健康作用的活性微生物,当机体摄入足够数量的益生菌,益生菌能在宿主肠道内定植,可以恢复并维持宿主肠道菌群的平衡。益生菌可作为预防复发性艰难梭菌感染的辅助治疗,同时在缓解炎症性肠病方面也有较好的效果。     

粪菌移植在临床治疗中的研究进展

粪菌移植的历史可以追溯到中国东晋时期。大量研究证实粪菌移植有可能成为许多疾病的有效治疗方法,现已逐渐应用于临床上并取得较好的疗效。粪菌移植可以通过增加短链脂肪酸,特别是丁酸盐的产量来减少肠道通透性,从而降低疾病的严重程度,这有助于维持上皮屏障的完整性。粪菌移植还可以通过抑制Th1分化、T细胞活性、白细胞粘附和炎症因子的产生来恢复免疫生态失调。目前对粪菌移植的研究主要集中在治疗艰难梭菌感染,但其他领域对粪菌移植研究的热情也日益高涨,如用于治疗炎症性肠病、代谢综合征和肠易激综合征等。本文对最新的粪菌移植在临床治疗中的研究进展作一综述。     

益生菌的应用现状和发展前景

益生菌是一类严格选择的，如果给予足够的量，能够为宿主带来健康益处的活性微生物。常见的具有益生功能的微生物，包括传统益生菌乳酸菌(lactic acid bacteria)和酵母菌(Saccharomyces)等，以及下一代益生菌普拉梭菌(Faecalibacterium prausnitzii)、脆弱拟杆菌(Bacteroides fragilis)、嗜黏蛋白阿克曼菌(Akkermansia muciniphila)和普雷沃氏菌(Prevotella copri)等。益生菌与人体健康之间存在密切的关系，这些微生物可通过肠道刺激胃肠道反应或直接作用于口腔、阴道、皮肤等其他部位以调节宿主健康。因此，它们在食品、种植业、畜牧业以及医疗领域中得到广泛应用，成为改善宿主健康的有力工具。本文对乳酸菌等传统益生菌以及嗜黏蛋白阿克曼菌等下一代益生菌的功能的开发与应用进行了综述，总结了这几种益生菌在食品生产、疾病治疗以及农业生产等方面的应用潜力，展望了益生菌资源研究与应用的发展趋势，以期为研究新老益生菌功能的开发与应用提供参考。     

黏质阿克曼菌及其代谢物短链脂肪酸与溃疡性结肠炎肠黏膜屏障的相关性研究

溃疡性结肠炎(ulcerative colitis, UC)已成为当今世界范围内的发病率高、患病人数多、病程缠绵的终身难治性疾病。而黏质阿克曼菌(Akkermansia muciniphila,A.muciniphila)及其代谢物短链脂肪酸(short chain fatty acid, SCFA)是近年来发现的对UC肠黏膜屏障具有保护作用的益生菌及代谢物,但其具体作用机制有待归纳和总结。因此本文从肠黏膜机械、化学、免疫及生物屏障这四个角度综合分析近年来的相关研究,试图探讨A. muciniphila和SCFA对肠黏膜屏障的具体作用机理,为研究UC的发病机制、治疗手段提供新视角和新思路。     

Akkermansia muciniphila alleviates high-fat-diet-related metabolic-associated fatty liver disease by modulating gut microbiota and bile acids

It has been reported that Akkermansia muciniphila improves host metabolism and reduces inflammation; however, its potential effects on bile acid metabolism and metabolic patterns in metabolic-associated fatty liver disease (MAFLD) are unknown. In this study, we have analysed C57BL/6 mice under three feeding conditions: (i) a low-fat diet group (LP), (ii) a high-fat diet group (HP) and (iii) a high-fat diet group supplemented with A. muciniphila (HA). The results found that A. muciniphila administration relieved weight gain, hepatic steatosis and liver injury induced by the high-fat diet. A. muciniphila altered the gut microbiota with a decrease in Alistipes, Lactobacilli, Tyzzerella, Butyricimonas and Blautia, and an enrichment of Ruminiclostridium, Osclibacter, Allobaculum, Anaeroplasma and Rikenella. The gut microbiota changes correlated significantly with bile acids. Meanwhile, A. muciniphila also improved glucose tolerance, gut barriers and adipokines dysbiosis. Akkermansia muciniphila regulated the intestinal FXR-FGF15 axis and reshaped the construction of bile acids, with reduced secondary bile acids in the caecum and liver, including DCA and LCA. These findings provide new insights into the relationships between probiotics, microflora and metabolic disorders, highlighting the potential role of A. muciniphila in the management of MAFLD.     

嗜粘蛋白阿克曼菌在糖尿病和肥胖中的作用

肠道微生物在平衡健康与疾病的过程中起着重要作用。嗜粘蛋白阿克曼菌(Akkermansia muciniphila)是肠道微生物中的一种,其在降解肠道粘蛋白方面的特性使其成为肠腔与宿主细胞黏膜界面的关键生物。嗜粘蛋白阿克曼菌与肥胖、糖尿病、心血管代谢疾病和低度炎症呈负相关。口服嗜粘蛋白阿克曼菌可改善小鼠代谢疾病的相关症状,嗜粘蛋白阿克曼菌有望成为治疗2型糖尿病和肥胖的候选药物。本综述通过总结现有关于嗜粘蛋白阿克曼菌在糖尿病和肥胖症中发挥作用的研究,指出嗜粘蛋白阿克曼菌调节宿主和肠道微生物群之间相互作用可能存在的机制,为嗜粘蛋白阿克曼菌的进一步研究和糖尿病的新药研发提供思路。     

黏蛋白阿克曼菌辅助治疗恶性肿瘤的研究进展

恶性肿瘤是威胁人类健康的全球重大公共卫生问题,多种方法联合,特别是以靶向治疗联合免疫治疗为主的治疗手段,在一定程度延缓了恶性肿瘤的发展,提高了患者的近期生存率,但这些治疗方法并不能覆盖所有患者,远期疗效仍然有限。因此,如何提高患者的生存质量和远期生存率,降低死亡率,成为当前亟待解决的关键问题。近年来越来越多的研究显示肠道微生物的分布与恶性肿瘤的发生、发展密切相关,或可成为治疗恶性肿瘤的新辅助方法,特别是嗜黏蛋白阿克曼菌（Akkermansia muciniphila）的报道较多,然而,关于该菌在恶性肿瘤辅助治疗中安全性和有效性的文献报道尚不多见。因此,本文旨在通过收集近年来嗜黏蛋白阿克曼菌在恶性肿瘤方面的文献,将其研究成果和应用结果进行归纳、分析,以期为临床综合治疗提供一定的药物选择。     

The effects of light on sex determination in gametophytes of the fern <Emphasis Type="Italic">Ceratopteris richardii</Emphasis>

The sexuality of homosporous fern gametophytes is usually determined by antheridiogen, a pheromone that promotes maleness. In this work the effect of photomorphogenically active light on antheridiogen-induced male development was examined for gametophytes of Ceratopteris richardii. Although blue light did not affect sensitivity to Ceratopteris antheridiogen (A_Ce) in wild-type gametophytes, it was found that the gametophytes of the her1 mutant, which are insensitive to A_Ce, developed into males when grown under blue light in the presence of A_Ce. Thus, we conclude that another A_Ce-signal transduction pathway activated by blue light exists latently in the gametophytes of C. richardii. Red light, on the other hand, suppressed male development. Because simultaneous red and blue light-irradiation did not promote male development in the her1 gametophytes, the action of red light seems to dominate that of blue light. The results of experiments with a photomorphogenic mutant also suggested that phytochrome may be involved in the action of red light.     

A Preliminary Study Examining the Binding Capacity of Akkermansia muciniphila and Desulfovibrio spp., to Colonic Mucin in Health and Ulcerative Colitis

Background

Akkermansia muciniphila and Desulfovibrio spp. are commensal microbes colonising the mucus gel layer of the colon. Both species have the capacity to utilise colonic mucin as a substrate. A. muciniphila degrades colonic mucin, while Desulfovibrio spp. metabolise the sulfate moiety of sulfated mucins. Altered abundances of these microorganisms have been reported in ulcerative colitis (UC). However their capacity to bind to human colonic mucin, and whether this binding capacity is affected by changes in mucin associated with UC, remain to be defined.

Methods

Mucin was isolated from resected colon from control patients undergoing resection for colonic cancer (n = 7) and patients undergoing resection for UC (n = 5). Isolated mucin was purified and printed onto mucin microarrays. Binding of reference strains and three clinical isolates of A. muciniphila and Desulfovibrio spp. to purified mucin was investigated.

Results

Both A. muciniphila and Desulfovibro spp. bound to mucin. The reference strain and all clinical isolates of A. muciniphila showed increased binding capacity for UC mucin (p < .005). The Desulfovibrio reference strain showed increased affinity for UC mucin. The mucin binding profiles of clinical isolates of Desulfovibrio spp. were specific to each isolate. Two isolates showed no difference in binding. One UC isolate bound with increased affinity to UC mucin (p < .005).

Conclusion

These preliminary data suggest that differences exist in the mucin binding capacity of isolates of A. muciniphila and Desulfovibrio spp. This study highlights the mucin microarray platform as a means of studying the ability of bacteria to interact with colonic mucin in health and disease.     

大蒜浸出液对平菇细菌性褐斑病病原菌托拉斯假单胞杆菌的抑菌作用

【背景】由托拉斯假单胞杆菌(Pseudomonas tolaasii)引起的平菇细菌性褐斑病在国内外大面积发生,导致产量降低,并有潜在的安全风险,寻找安全有效的抑菌剂对产业发展具有重要意义。【目的】通过5种不同溶剂提取得到大蒜浸出液,测定其对平菇细菌性褐斑病病原菌托拉斯假单胞杆菌的抑制作用,同时检测其对平菇菌丝生长的作用。【方法】利用抑菌圈法测定5种不同的大蒜浸出液对托拉斯假单胞杆菌的抑菌作用,利用平板扩散法筛选能促进平菇菌丝生长的药剂及适宜的浓度。【结果】5种大蒜浸出液原液对托拉斯假单胞杆菌均有显著的抑菌活性,其中大蒜山杏壳木醋液浸出原液抑菌效果最强。不同浓度的大蒜浸出液抑菌作用比较发现,浓度为10%的大蒜山杏壳木醋液浸出液具有较好的抑菌效果,其抑菌效果与0.33 mg/mL的链霉素相当,并对平菇菌丝生长有显著的促进作用,菌丝生长速度显著大于对照,并且菌丝浓密,边缘整齐。【结论】本研究为大蒜与山杏壳木醋液复配药剂防治平菇细菌性褐斑病奠定了实验基础。     

Recent Advancements in the Development of Modern Probiotics for Restoring Human Gut Microbiome Dysbiosis

A healthy gut is predominantly occupied by bacteria which play a vital role in nutrition and health. Any change in normal gut homeostasis imposes gut dysbiosis. So far, efforts have been made to mitigate the gastrointestinal symptoms using modern day probiotics. The majority of the probiotics strains used currently belong to the genera Lactobacillus, Clostridium, Bifidobacterium and Streptococcus. Recent advancements in culturomics by implementing newer techniques coupled with the use of gnotobiotic animal models provide a subtle ground to develop novel host specific probiotics therapies. In this review article, the recent advances in the development of microbe-based therapies which can now be implemented to treat a wide spectrum of diseases have been discussed. However, these probiotics are not classified as drugs and there is a lack of stringent law enforcement to protect the end users against the pseudo-probiotic products. While modern probiotics hold strong promise for the future, more rigorous regulations are needed to develop genuine probiotic products and characterize novel probiotics using the latest research and technology. This article also highlights the possibility of reducing antibiotic usage by utilizing probiotics developed using the latest concepts of syn and ecobiotics.